Transgene Overview
- Year Founded
-
1979
- Status
-
Public
- Employees
-
160
- Stock Symbol
-
TNG
- Investments
-
4
- Share Price
-
$0.80
- (As of Friday Closing)
Transgene General Information
Description
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
Contact Information
Website
www.transgene.comCorporate Office
- 400 Boulevard Gonthier d'Andernach
- Parc dInnovation - CS80166
- 67405 Illkirch-Graffenstaden
- France
Corporate Office
- 400 Boulevard Gonthier d'Andernach
- Parc dInnovation - CS80166
- 67405 Illkirch-Graffenstaden
- France
Transgene Timeline
Transgene Stock Performance
As of 13-Nov-2026, Transgene’s stock price is $0.80. Its current market cap is $222M with 278M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.80 | $0.81 | $0.75 - $1.57 | $222M | 278M | 118K | -$0.20 |
Transgene Financials Summary
As of 30-Jun-2026, Transgene has a trailing 12-month revenue of $807K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 102,630 | 323,004 | 77,762 | 146,798 |
| Revenue | 807 | 553 | 332 | 1,569 |
| EBITDA | (37,528) | (39,274) | (33,477) | (22,278) |
| Net Income | (39,543) | (42,327) | (36,760) | (24,161) |
| Total Assets | 142,197 | 163,068 | 43,885 | 49,983 |
| Total Debt | 0 | 0 | 18 | 1,389 |
Transgene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Transgene Comparisons
Industry
Financing
Details
Transgene Competitors (44)
One of Transgene’s 44 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Innate Pharma | Formerly VC-backed | Marseille, France | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA |
Transgene Patents
Transgene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026041811-A1 | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell | Pending | 23-Aug-2024 | ||
| WO-2024062098-A1 | Recombinant pseudocowpox virus encoding an interleukin-12 | Inactive | 23-Sep-2022 | ||
| AU-2023326730-A1 | Chimeric poxviruses | Pending | 18-Aug-2022 | ||
| EP-4573113-A1 | Chimeric poxviruses | Pending | 18-Aug-2022 | ||
| JP-2025528219-A | Chimeric poxviruses | Pending | 18-Aug-2022 | C12N7/00 |
Transgene Signals
Transgene Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Transgene Investments (4)
Transgene’s most recent deal was a PE Growth/Expansion with Tasly Biopharmaceuticals for . The deal was made on 28-Jun-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tasly Biopharmaceuticals | 28-Jun-2019 | PE Growth/Expansion | Drug Discovery | ||
| Tasly Biopharmaceuticals | 01-Jul-2018 | Corporate | Drug Discovery | ||
| Active Biomarkers | 01-Jan-2011 | Joint Venture | Laboratory Services (Healthcare) | ||
| Transgene Tasly (Tianjin) BioPharmaceutical | 01-Jan-2010 | Joint Venture | Pharmaceuticals |
Transgene ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.67 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Transgene Exits (2)
Transgene’s most recent exit was on 01-Jan-2011 from Active Biomarkers. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Active Biomarkers | 01-Jan-2011 | Completed |
|
||
| Transgene Tasly (Tianjin) BioPharmaceutical | 01-Jan-2010 | Joint Venture | Completed |
|
Transgene FAQs
-
When was Transgene founded?
Transgene was founded in 1979.
-
Where is Transgene headquartered?
Transgene is headquartered in Illkirch-Graffenstaden, France.
-
What is the size of Transgene?
Transgene has 160 total employees.
-
What industry is Transgene in?
Transgene’s primary industry is Drug Discovery.
-
Is Transgene a private or public company?
Transgene is a Public company.
-
What is Transgene’s stock symbol?
The ticker symbol for Transgene is TNG.
-
What is the current stock price of Transgene?
As of 13-Nov-2026 the stock price of Transgene is $0.80.
-
What is the current market cap of Transgene?
The current market capitalization of Transgene is $222M.
-
What is Transgene’s current revenue?
The trailing twelve month revenue for Transgene is $807K.
-
Who are Transgene’s competitors?
Moderna, Agenus, Innate Pharma, TME Pharma, and Arcus Biosciences are some of the 44 competitors of Transgene.
-
What is Transgene’s annual earnings per share (EPS)?
Transgene’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process